Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension

Inclusion Criteria: 1. Male or female participants aged 18-75 years old; 2. 24h ambulatory systolic BP ≥130mmHg and \<150mmHg, and 24h ambulatory diastolic BP \<100mmHg after at least 4 weeks of combined treatment with 3 antihypertensive drugs (including a diuretic); 3. The ultrasound measured inferior perirenal adipose tissue ≥8 cm3 (with the superior-inferior diameter, left-right diameter, and anterior-posterior diameter all needing to be ≥20 mm); 4. Be willing to participate in the trial, and be able to visit doctors by himself or herself; 5. Sign the informed consent form. Exclusion Criteria: 1. Secondary hypertension; 2. Occurrence of myocardial infarction, malignant arrhythmia, severe renal failure, or stroke within 6 months; 3. Ambulatory BP monitoring was invalid (\<70% valid readings, or \<20 daytime readings or \<7 nighttime readings); 4. Alanine transaminase (ALT), aspartate transaminase (AST), or total bilirubin (TBL) above twice the normal range; eGFR (CKD-EPI) \<45mL/min/1.73m2; 5. Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (glycated hemoglobin ≥8.5%); 6. Single functionally normal kidney or presence of renal malignant tumor; 7. Bilateral skin diseases at renal region that are not suitable for the therapy; 8. Women in pregnancy, lactating, or planning for pregnancy; 9. Other concomitant diseases that are considered not suitable for participation in the trial; 10. Patients have contraindications to angiotensin receptor-neprilysin inhibitor (ARNIs), thiazide-like diuretic drugs, or calcium channel blocker (CCBs); 11. Non-compliant patients.